Qinhua Cindy Ru
Dr. Ru holds near 20 years of global pharmaceutical oncology innovative drug development working experience. She has been working at Merck Oncology, Novartis Oncology, Exelixis, and Pfizer Oncology with raising roles. She was the main contributor for vorinostat MAA submission (Merck Oncology), the global clinical trial head for burparlisib (BKM120) clinical development from Phase I first-in-human to Phase III pivotal trial for 6 consecutive years when working at Novartis, senior director and clinical science lead of METEOR trial that led to the NDA and MAA approval of CaboMetyx (Exelixis), and was the Hematology Asset Team Lead and
“CEO” of inotuzumab ozogamicin and gemtuzumab ozogamicin that were successfully marketed as Besponsa® and Mylotarg® in US. Over years, Dr. Ru lead and successfully delivered multiple global development projects of innovative oncology drugs. She was the winner of Novartis President Award and received performance awards at every global pharmaceutical company that she had worked for. She has also shortly worked as CSO for Sihuan Pharmaceutical Group Holding Company and CARsgen Therapeutics from late 2016 to late 2017. In late 2017, Dr. Ru founded CRC Oncology, a non-profit research organization with a clear mission to incubating global start-ups in oncology advanced therapy area. Before joining industry, Dr. Ru was the Principal Scientist and sub-investigator in the Clinical Breast Care Project (CBCP), a breast cancer vaccination development program sponsored by the US Department of Defense and conducted at Walter Reed Army Medical Centre. Dr. Ru acquired her Ph.D. degree in Chemistry from Tsinghua University (Beijing, China) in January 2001. She further
completed her Post-Doctoral training in the US Department of Defense sponsored Los Alamos National
Laboratory Bioscience Division (Los Alamos, NM) in 2003.